In this article, we are going to take a look at where Bruker Corporation (NASDAQ:BRKR) stands against the other medical technology stocks. The MedTech sector is crucial in healthcare, which ...

These seven high-quality ETFs provide current income and offer the opportunity for growth over time.

French President Emmanuel Macron on Monday fact-checked his US counterpart Donald Trump on aid for Ukraine as they met at the White House on the third anniversary of Russia's invasion. During a ...

As it happens, Bruker issued 9.5% more new shares over the last year. That means its earnings are split among a greater number of shares. Per share metrics like EPS help us understand how much ...

Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, LS2 9JT Leeds, U.K. Astbury Centre for Structural ...

Department of Clinical Microbiology, Umeå University, Umeå 901 87, Sweden Wallenberg Centre for Molecular Medicine (WCMM), Umeå University, Umeå 901 87, Sweden Umeå Centre for Microbial Research (UCMR ...

Stifel lowered the firm’s price target on Bruker (BRKR) to $57 from $70 and keeps a Hold rating on the shares. Bruker continues to show strength in its portfolio with a significant backlog ...

Stifel Nicolaus analyst Daniel Arias maintained a Hold rating on Bruker (BRKR – Research Report) today and set a price target of $57.00. The company’s shares closed yesterday at $51.15.

2025 Non-GAAP EPS Guidance: $2.67 to $2.72, representing 11% to 13% growth. Bruker Corp (NASDAQ:BRKR) reported a strong Q4 2024 with a 14.6% year-over-year increase in revenues, reaching $979.6 ...

Bruker (BRKR) reported $979.6 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 14.6%. EPS of $0.76 for the same period compares to $0.70 a year ago.